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Abstract
Aims The clinical effectiveness of primary prevention implantable cardioverter deﬁbrillator (ICD) therapy is under debate.
The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Deﬁ-
brillators (EU-CERT-ICD) aims to assess its current clinical value.
Methods and results The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicentre obser-
vational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischae-
mic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. This sample will include
1500 patients at their ﬁrst ICD implantation and 750 patients who did not receive a primary prevention ICD despite having an
indication for it (non-randomized control group). The primary endpoint is all-cause mortality; the co-primary endpoint in ICD
patients is time to ﬁrst appropriate shock. Secondary endpoints include sudden cardiac death, ﬁrst inappropriate shock, any
ICD shock, arrhythmogenic syncope, revision procedures, quality of life, and cost-effectiveness. At baseline (and prior to
ICD implantation if applicable), all patients undergo 12-lead electrocardiogram (ECG) and Holter ECG analysis using multiple
advanced methods for risk stratiﬁcation as well as detailed documentation of clinical characteristics and laboratory values. Ge-
netic biobanking is also organized. As of August 2018, baseline data of 2265 patients are complete. All subjects will be followed
for up to 4.5 years.
Conclusions The EU-CERT-ICD study will provide a necessary update about clinical effectiveness of primary prophylactic ICD
implantation. This study also aims for improved risk stratiﬁcation and patient selection using clinical and ECG risk markers.
STUDY DES IGN
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Introduction
An estimated 500 000 sudden cardiac deaths (SCD) occur in
the European Union (EU) annually, the majority of which are
caused by malignant ventricular arrhythmias.1 Large prospec-
tive, randomized multicentre studies have established that
implantable cardioverter deﬁbrillator (ICD) therapy is effec-
tive for primary prevention of SCD and improves total survival
in patient populations.2,3 ICDs are considered routine treat-
ment after implementation to international guidelines.4,5
More than a decade after publication of the landmark trials,
there is evidence that all-cause mortality and appropriate
shock rates have decreased and vary widely with age and
co-morbidities.6,7 Inappropriate and appropriate shocks have
been reduced after optimization of ICD programming.8,9 It
was demonstrated from heart failure trials that the rate of
SCD declined over the last decades.10 As a consequence, a
large number of ICD patients never receive appropriate
shocks or die prior to any appropriate ICD therapy as the risk
of non-arrhythmic death outweighs the risk of arrhythmic
death.11 Thus, improved selection of patient subgroups with
a sufﬁciently high mortality beneﬁt from ICD therapy is ur-
gently required.12,13 Useful parameters for risk stratiﬁcation,
for example, electrophysiological and electrocardiographic
markers, parameters from cardiovascular history, biomarkers,
and possible combinations are underused.14–16 In 2012, the
design of a randomized trial seemed ethically close to impos-
sible due to the wide implementation of ICD therapy and un-
equivocal guidelines. Instead, we set out to conduct a large
prospective non-randomized cohort study. We aimed to re-
evaluate beneﬁts from prophylactic ICD therapy and to test
multiple combinations of risk factors to predict the risk of
ICD shocks vs. the competing risk of non-arrhythmic mortality.
Study objectives
The ‘EUropean Comparative Effectiveness Research to assess
the use of primary prophylacTic Implantable Cardioverter De-
ﬁbrillators (EU-CERT-ICD)’ was funded by the European
Community’s Seventh Framework Programme as a modular
research project to study the effectiveness of prophylactic
ICDs. In addition to the described prospective study, a retro-
spective registry17 and meta-analyses in primary prophylactic
ICD patients were set up18,19 (Figure 1). Over the course of
the project, several original papers20–27 and editorials28–33
have been published from the various work packages. At the
outset of the project, its primary objectives were as follows:
• to characterize all-cause mortality in a prospective patient
cohort of ICD candidates newly implanted for primary pro-
phylaxis of SCD and compare with a non-randomized con-
trol group;
• to determine prespeciﬁed clinical baseline characteristics
contributing to the risk of the primary outcomes, that is,
all-cause mortality and ﬁrst appropriate shock;
• to deﬁne subgroups within the cohort with a lower or
higher beneﬁt from ICD treatment;
• to assess simple and cost-effective electrocardiographic
noninvasive risk stratiﬁcation techniques;
• to identify predictors for appropriate shocks using electro-
cardiogram (ECG)-related parameters and autonomic param-
eters as well as co-morbidities and laboratory parameters;
• to characterize subgroups within the cohort with a deviat-
ing risk for appropriate shock, in particular focusing on the
role of sex category;
• to gather a blood sample from each participating patient
(biobanking) to perform a genome analysis for risk stratiﬁ-
cation; and
• to provide outcome data as a basis for extensive health
economic evaluation of ICD use and quality of life (QoL)
including subgroups and country-speciﬁc differences.
Study design
The EU-CERT-ICD prospective trial is an investigator-initiated
non-randomized, open, controlled, observational multicentre
cohort study in 2250 analysable patients with ischaemic or di-
lated cardiomyopathy being candidates for receiving a primary
prevention ICD by current guidelines. In the ICD treatment
group, we aimed to enrol 1500 analysable patients at their ﬁrst
ICD implantation. Using the large disparities of ICD implant
rates across Europe,34 it was considered to ﬁnd a non-
randomized group of 750 comparable patients without ICDs
to generate data on current ICD survival beneﬁt. In the statisti-
cal design, differences between the ICD group and the control
group in terms of relevant prognostic factors are compensated
by appropriate statistical methodology yielding a hazard ratio
that indicates the effect of the primary prophylactic ICD on
the primary endpoint, all-cause mortality. All control patients
are required to fulﬁl the primary prevention guideline indica-
tion, and reasons for non-ICD status have to be unrelated to
the study, to be documented in the electronic case report form
(eCRF) (did patient refuse to be implanted an ICD, did physician
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not recommend ICD implantation, and is ICD not sufﬁciently
reimbursed by health care system). All patients receive optimal
pharmacological treatment. In a total of 15 EU or EU-
associated (Switzerland) countries, 44 clinical centres enrolled
patients (Figure 2). Sites and countries were chosen to include
highly experienced investigators representative of European
cardiovascular medicine, often nationally leading centres.
Expecting a dropout rate of 10%, a total number of 2500 pa-
tients was initially conceived; however, after the dropout rate
was observed to be considerably lower, 2310 patients were
targeted. All centres were encouraged to enrol patients con-
secutively from their screening sources. The Seventh Frame-
work Programme project organization is shown in Figure 1.
Ethics
Approval was given by all local ethics committees. All patients
gave their informed written consent prior to inclusion. The
study is conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice (GCP) principles. The study
is registered at www.clinicaltrials.gov (NCT02064192).
Endpoints
Primary endpoints
The primary endpoint is all-cause mortality. Co-primary end-
points for risk prediction in the ICD patients are time to death
and time to ﬁrst appropriate shock.
Secondary endpoints
Secondary endpoints of the study are as follows:
• cardiac mortality,
• SCD,
• non-cardiac mortality,
• ﬁrst inappropriate shock,
• any ICD shock (appropriate or inappropriate),
• arrhythmogenic syncope or successful resuscitation for
ventricular tachyarrhythmias,
• ECG-documented paroxysmal or permanent atrial ﬁbrilla-
tion (deﬁned as an atrial tachyarrhythmia >250/min last-
ing >30 s),
• revision, replacement, or upgrade/downgrade device
procedures,
• QoL, and
• cost-effectiveness and estimated total costs.
Inclusion and exclusion criteria
Patients are eligible for enrolment if they fulﬁl the following
inclusion criteria:
• patients with ischaemic or dilated cardiomyopathy;
• left ventricular ejection fraction (LVEF) ≤ 35% and New
York Heart Association (NYHA) functional classes II–III (or
NYHA functional class I and LVEF ≤ 30%);
• indication for primary prevention ICD treatment according
to current European Society of Cardiology guidelines,4 in-
cluding pharmacologic treatment of heart failure and
Figure 1 Overview of the EU-CERT-ICD project structure. QoL, quality of life; WP, work package.
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correct timing from diagnosis of underlying heart disease
and acute myocardial infarction;
• age ≥ 18 years; and
• written informed consent to participate in the study.
Patients may not fulﬁl one of the following exclusion criteria:
• patients with a secondary prophylactic ICD indication;
• planned implantation of a device for cardiac
resynchronization therapy (CRT deﬁbrillator or CRT pace-
maker), or clearly indicated according to guidelines;
• unstable cardiac condition (i.e. acute ischaemia or NYHA IV);
• persistent higher degree atrioventricular block (in sinus
rhythm);
• previous pacemaker or cardiac device therapy; and
• limited life expectancy ≤1 year.
Patients with atrial ﬁbrillation are accepted up to a maximum
of 15%.
Endpoint adjudication
The external endpoint committee will provide blinded adjudi-
cation of all death, shock, resuscitation, and syncope events.
Each death will be classiﬁed as SCD,35 cardiac, or non-cardiac.
ICD shocks will be adjudicated based on review of device
electrograms and classiﬁed as appropriate or inappropriate.
An appropriate ICD shock is classiﬁed as (i) primarily deliv-
ered in the ventricular ﬁbrillation (VF) zone, (ii) delivered as
a backup to failed anti-tachycardia pacing (ATP) in the ven-
tricular tachycardia (VT) zone, or (iii) delivered after accelera-
tion of a failed ATP into the VF zone.
Crossover between study groups
Crossover of patients from the control group to the ICD group
is not encouraged but is allowed at the discretion of the
treating physicians. Typical reasons were the occurrence of
malignant arrhythmias or the suspicion of arrhythmogenic
syncope. The date of ICD implantation and manufacturer
are noted in the eCRF; subsequently, the patient remains in
the study with documentation of ICD events and program-
ming. Statistical analysis will occur on an intention-to-treat
basis; an on-treatment analysis is possible.
Figure 2 Clinical study sites in the European Union.
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Study protocol
A graphic outline of the study protocol is shown in Figure 3.
A 12-lead Holter ECG (CM 3000-12 BT; Getemed,
Teltow/Germany) is recorded at 1 kHz sampling frequency
for 24 h prior to ICD implantation in the ICD group. Holter data
are collected for the purposes of ECG-based risk stratiﬁcation.
They will be analysed for the number of premature ventricular
complexes, number of episodes and rate of non-sustained VT,
short-term variability of the QT interval,36 respiration trig-
gered sinus arrhythmia,37 modiﬁed moving average T-wave
alternans,38 periodic repolarization dynamics,39 heart rate
variability,40 and heart rate turbulence including standard
deviation of RR intervals, root mean square of successive
differences in RR intervals, frequency domain heart rate vari-
ability parameters (low frequency/high frequency), turbu-
lence onset, turbulence slope, acceleration capacity, and
deceleration capacity.41,42 From the 12-lead ECG extracted
from suitable episodes of the 12-lead Holters, total cosine R-
to-T (unitless), relative T-wave residuum (%), T-wave morphol-
ogy dispersion (°), T-wave loop dispersion (unitless),43 T-peak-
to-T-end interval (ms), J-point elevation (mV), fractionation in-
dex (unitless),44 fragmented QRS,26 and early repolarization45
will be determined. Some of these measurements are not pos-
sible in atrial ﬁbrillation; therefore, the number of patients
with atrial ﬁbrillation is limited to 15%. During every Holter re-
cording, a dedicated autonomic provocation schedule (10 min
supine, 10 min standing, 10 min supine, and 10 min light exer-
cise) is performed during the morning hours to allow subse-
quent study of autonomic responsiveness. Echocardiography
is performed to measure LVEF using Simpson’s method.46 Un-
derlying cardiac disease, NYHA functional class, pulse rate,
resting blood pressure, weight, height, and cardiovascular
pharmacological treatment are documented along with the
presence or absence of the following co-morbidities: periph-
eral arterial disease, cerebral vascular disease, pulmonary
disease, diabetes mellitus, hypertension, sleep apnoea,
tobacco use, and anymalignant disease within the last 5 years.
Standard laboratory parameters are recorded, including creat-
inine, estimated glomerular ﬁltration rate, serum blood urea
nitrogen, and N-terminal pro BNP or BNP. An EDTA blood
sample for biobanking will be taken. All study baseline tests
had to be completed before implantation. Routine ICD
implantation is not part of this observational study. Written
informed consent for ICD implantation is obtained indepen-
dently of the study.
Follow-up
All ICD patients are followed in the outpatient clinic every 3
to 6 months or remotely by telecardiologic follow-up.
Episodes of shock or ATP are stored as electrograms for adju-
dication; programming changes are recorded. Patients in the
non-ICD control group are scheduled for visits every 6 to
12 months according to their clinical needs. In both groups,
information can also be retrieved from hospital records, via
telephone and/or mail from patients, relatives, general prac-
titioners, or local authorities. If a patient undergoes heart
transplant or implantation of a ventricular assist device,
follow-up is censored on that date without an event counted.
Implantable cardioverter deﬁbrillator
programming
For this study, mandatory ICD programming was established.
A VT therapy (200–250 b.p.m.) and a VF therapy
(>250 b.p.m.) zone were programmed, with a supplementary
monitor zone (170–200 b.p.m.). VT was treated by ATP
followed by shocks of maximum output. VF was treated by
ATP during charge (if applicable) and shocks of maximum
output. ICD programming could be individualized by the
physician on clinical grounds.
Figure 3 Study protocol. ICD, implantable cardioverter deﬁbrillator.
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Quality of life and health economics
Quality of life is assessed at baseline and annually during
follow-up. Patients will ﬁll out the SF-36 Questionnaire for
general QoL,47 the MacNew Questionnaire for disease-
speciﬁc QoL,48 and the Florida Patient Acceptance Survey
for ICD acceptance.49 Health economics questionnaires
are assessed at baseline and during follow-up visits in
German-speaking patients in Germany and Switzerland
(questionnaire is validated only in the German language).
QoL-adjusted cost-effectiveness will be estimated from actual
cost comparisons and Markov decision models with attention
to subgroups, regional, and sex comparisons.
Study organization
Clinical research organization services are provided by
the Clinical Trial Unit (Klinisches Studienmanagement –
Studienzentrum) of the University Medical Center Göttingen
providing contract management, regulatory services, eCRFs,
data management, and central and on-site monitoring.
Web-based data capture and data collection are performed
in secuTrial (current version, www.secutrial.com) according
to GCP standards. Data quality is continuously monitored in
all centres using central monitoring and query management.
Regular on-site monitoring is additionally organized and con-
ducted by the Clinical Trial Unit or a local freelancer. The main
purpose of monitoring is to ensure optimal data quality and
guarantee that the study is conducted, recorded, and re-
ported in accordance with the study protocol and GCP guide-
lines. Patient safety is not an issue in an observational trial.
The Consortium Steering Committee is formed by the over-
all project coordinator, work package leaders, and the lead
statistician.
Sample size calculation
Sample size calculations were carried out for the comparison
of ICD patients with controls regarding mortality and for strat-
iﬁcation of the ICD cohort with regard to appropriate shocks
and mortality. We start here with the former. In the Identiﬁca-
tion and Therapeutic Targeting of Common Arrhythmia Trigger
Mechanisms clinical study,50 an annual all-cause mortality of
about 4% was observed for high-risk patients. A similar mortal-
ity of 4.5% was observed by Smith et al.51 Assuming an annual
all-cause mortality of 4.5% in the ICD patients, exponential sur-
vival times, and a hazard ratio of 0.7 as observed in Multicen-
ter Automatic Deﬁbrillator Implantation Trial II (MADIT-II),2
recruitment over 3 years, and total study duration of 4 years,
a sample of 1500 ICD patients and 750 control patients yields
a power of 80% at the usual two-sided signiﬁcance level of
5%. From preliminary analyses of registry data in 1272 ICD
patients23 and from own prospective data from 282 ICD pa-
tients,22 we inferred that independent binary or dichotomized
risk stratiﬁers (electrophysiological parameters, biomarkers,
and other patients’ characteristics) provide hazard ratios be-
tween 1.5 and 2.5. Thus, the sample size calculation of this
study is based on a hazard ratio of 2 between a high-risk and
a low-risk group of patients for some independent predictor
variables. It was further assumed that about 20–40% of pa-
tients exhibit a lower overall risk with decreased annual all-
cause mortality and that about 50% of patients exhibit a lower
risk with regard to the annual appropriate ICD shock rate. As-
suming a ratio of group sizes of 2:1, Schoenfeld’s formula for
time-to-event data52 yielded that 122 deaths are required to
achieve a power of 95% for a two-sided test at the usual
two-sided signiﬁcance level of 5% assuming a hazard ratio of
2. Correspondingly, 108 appropriate ICD shocks are required
if the ratio of group sizes is 1:1 (equal group sizes for high-risk
and low-risk patients). In the EUTrigTreat clinical study,50 an
annual appropriate ICD shock rate of about 4.5% was observed
for high-risk patients. Higher rates of ICD shock (6%) as com-
pared with the Sudden Cardiac Death in Heart Failure Trial
(SCD-HeFT) study (5%) were published in 2005.3 With a hazard
ratio of 2, we assume an annual all-cause mortality and an an-
nual appropriate ICD shock rate of about 2.25% for low-risk pa-
tients. Assuming exponentially distributed waiting times, 108
events can be expected to be observed within 4 years as long
as at least a total of 1476 ICD patients are recruited into the
study in two equally sized groups deﬁned by the assessed
prognostic markers over a 3 year period. Adjusting for some
dropout, we aim to recruit 1500 patients with ICD into the
study. Because risk rates can vary between men and
women,53,54 the derived sample size was also checked with re-
spect to the detection of a gender-by-prognostic factor interac-
tion. A total of 122 events are sufﬁcient to detect a gender-by-
prognostic factor interaction with power of at least 80% at a
two-sided signiﬁcance level of 10% if the groups are equally
sized and the hazard ratios differ by a factor of 2.5 or larger.
A total of about 37 events is expected in women,54 providing
a power of at least 80% (90%) for hazard ratios larger or equal
to 2.5 (2.9) at the usual two-sided signiﬁcance level of 5% as-
suming equally sized groups. If the group is split in a ratio of
2:1, the power is at least 80% (90%) for hazard ratios in excess
of 2.6 (3.1). For the multivariate comparison of the primary
endpoint between the ICD group and the control group (alloca-
tion ratio 2:1), a total number of 279 events are necessary for a
clinically relevant hazard ratio of 0.7 at the usual two-sided sig-
niﬁcance level of 5%.
Statistical analyses
Patients who undergo an incomplete set of diagnostic base-
line tests after enrolment will not be automatically excluded.
Patients recruited and dropped out before the baseline
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diagnostic tests will not be analysed. Time-to-event outcomes
are summarized by Kaplan–Meier curves and estimates of
event probabilities at appropriate follow-up times will be
given with 95% conﬁdence intervals. For appropriate and in-
appropriate shocks, death is considered a censoring event
using competing risk adjustments.55 Cox proportional hazards
regression analyses or Fine and Gray proportional sub-
distribution hazard regression analyses are performed to
quantify the predictive value of multiple categorical variables
and dichotomized continuous variables on the primary and
secondary time-to-event endpoints without (e.g. mortality)
or with competing risks (e.g. shocks), respectively. The regres-
sion models will also include covariables such as age and sex
category that potentially could confound the biomarkers of
interest and ICD treatment. The independent predictive value
of any variable will be determined. Useful combinations of in-
dependently predictive variables will be grouped together in
order to establish prediction models or risk scores6,56,57 for
the prediction of mortality or ICD shocks or any of the
predeﬁned primary or secondary endpoints. Hazard ratios
will be reported with 95% conﬁdence intervals and P-values
testing the hypothesis of no effect. Diagnostic techniques will
be used to check the proportional hazards assumption. If
necessary, missing data will be dealt with using multiple im-
putation. Classiﬁcation models will be validated using cross-
validation. The problem of unbalanced clinical characteristics
between the ICD and control groups will be approached
by using multivariate analyses of all patients with the pres-
ence of the ICD as one of the factors inﬂuencing outcomes
but also by propensity score methods appropriate for non-
randomized studies and centre-by-centre comparisons.
Discussion
The EU-CERT-ICD study will provide a necessary update on
clinical effectiveness of primary prophylactic ICD implantation,
following the recent publication of the Danish Study to Assess
the Efﬁcacy of ICDs in Patients with Non-ischemic Systolic
Heart Failure onMortality trial.58 Large disparities in ICD treat-
ment that are multifactorial and cannot be explained by socio-
economic differences continue to exist between European
countries.34 Using multivariable regression statistics of the pri-
mary endpoint, we will be able to calculate an adequately
powered hazard ratio of the ICD survival effect (as the primary
measure of ICD beneﬁt) in the overall cohort and predeﬁned
subgroups. Valid risk scores for mortality and shock can be
provided. Concerning these outcomes, the results will be able
to conﬁrm known independent risk factors and possibly detect
new ones. A large number of useful parameters for risk strat-
iﬁcation, for example, electrocardiographic markers, cardio-
vascular history, biomarkers, and possible combinations can
be used,14–16 as exempliﬁed by other conceptual publications
from the ﬁeld.50,57,59,60 Cost-effectiveness in the overall trial
population and in subgroups and the variation in EU countries
can be analysed. The study will be an excellent tool to assess
the predictive value of several state-of-the-art advanced ECG
methods for application in the clinical decision-making in ICD
candidates.
Implantable cardioverter deﬁbrillator guidelines
and implantable cardioverter deﬁbrillator beneﬁt
An update of the current European Society of Cardiology
guidelines4 and incorporating the DANISH trial as the only re-
cent randomized ICD outcome trial (conducted 2008 to 2016)
is still pending. DANISH showed that ICD therapy currently
does not reduce mortality in all patients with non-ischaemic
cardiomyopathy.58 From the original DANISH data, it was
shown that increasing age is associated with loss of ICD
survival beneﬁt.61 Important outcomes in primary prevention
ICD patients—that is, overall mortality and shocks—have
improved considerably.8,23,58,17 It is therefore uncertain
whether the survival beneﬁt of prophylactic ICDs is still the
same. It had been hypothesized from original SCD-HeFT56
and MADIT-II62 data that patients with very high mortality
do not beneﬁt from prophylactic ICDs due to a high rate of
non-arrhythmic or non-cardiac deaths.63 Important sub-
groups, such as women,3,62 patients with advanced heart
failure,3,50 renal failure,64 or diabetics,65 may have an ICD
beneﬁt below average. Net beneﬁt of an ICD on survival de-
pends on the underlying risk of malignant ventricular arrhyth-
mias, as the device can reliably abort VT and VF, should they
occur. Side effects of device therapy, such as device revisions,
infections, and inappropriate shocks,8,66 must be weighed in.
In patients with low risk of life-threatening arrhythmias, risks
may outweigh beneﬁt; therefore, it is clinically useful to risk
stratify accurately. As an example, in patients with hypertro-
phic cardiomyopathy, an ICD is generally not recommended,
if the risk of SCD is predicted to be less than 0.8% per year.67
Current studies
In parallel to EU-CERT-ICD, the Dutch Outcome in Implantable
cardioverter-deﬁbrillator Therapy registry study funded by
Dutch health insurers will report similar outcomes including
cost-effectiveness in 1500 primary prophylactic ICD patients
from multiple implant centres in the Netherlands in late
2018.68 The randomized REevaluation of optimal treatment
Strategies for prEvenTion of Sudden Cardiac Death in patients
with ischemic cardiomyopathy trial was proposed to reassess
the effects of primary prophylactic ICD therapy in ischaemic
cardiomyopathy.69 Another trial probing the prophylactic in-
dication of deﬁbrillators—the randomized Re-evaluation of
Optimal Re-synchronisation Therapy in Patients with Chronic
Heart Failure trial in 2000 patients with an LVEF ≤ 35% and
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CRT treatment—is funded by the German health system70
and starting up.
Conclusion
Appropriate identiﬁcation of patient subgroups with signiﬁ-
cant mortality beneﬁt from ICD therapy remains critical,
and risk prediction models incorporating variables beyond
LVEF and NYHA functional class are warranted. Further ran-
domized ICD studies in prophylactic indications now seem
feasible. The EU-CERT-ICD study will prospectively test indica-
tion criteria for primary prophylactic ICD implantation and is
expected to provide important contemporary data to im-
prove patient selection.
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Appendix
List of EU-CERT-ICD clinical centres
Germany (13 centres, 507 patients): University Medical
Center Göttingen: M. Zabel, J. Seegers, L. Bergau,
G. Hasenfuß, P. Munoz-Exposito, T. Tichelbäcker, A. Kirova, S.
Schlögl, R. Sritharan, K. Jörß, J. Macken, M. Misdaq,
K. Rudolph (210); DZHK (German Center for Cardiovascular
Research), partner site Göttingen: M. Zabel, G. Hasenfuß,
T. Friede; University Hospital Tübingen: A. Bauer, C.
Meyer-Zürn, C. Eick (65); Technische Universität München,
Klinikum rechts der Isar: G. Schmidt, A. Müller, M. Dommasch,
D. Sinnecker (49); Klinikum Großhadern und Innenstadt,
Ludwig-Maximilians-Universität Munich: S. Kääb, M. Sinner,
A. Bauer (44); Klinikum Reinkenheide Bremerhaven: R.
Dissmann, U. Burmester (26); Vivantes Humboldt Klinikum
Berlin: S. Behrens, M. Gregor (21); Klinikum Ludwigsburg:
S. Stefanow, N. Rüb, C. Wolpert (20); Marienkrankenhaus
Bonn: D. Bimmel, C. Lieberz (19); University Hospital
Regensburg: J. Seegers, L. Maier (18); Klinikum Weiden:
R. Schwinger (12); Charité Campus Virchow Klinikum: F.
Blaschke, B. Pieske (12); Asklepios Klinik Hamburg-Barmbek:
G. Grönefeld (10); Herz im Zentrum Hannover: G. Klein,
A. Gardiwal (1).
Hungary (1 centre, 347 patients): Semmelweis University
Hospital Budapest: B. Merkely, G. Szeplaki, P. Perge.
Croatia (5 centres, 226 patients): Magdalena Klinika Krapinske
Toplice: J. Szavits Nossan, L. Rotkvić (110); KBC Sestre
Milosrdnice Zagreb: N. Pavlovic, S. Manola, O. Vinter, I. Benko
(70); KBC Rijeka: S. Brusic, E. Avdovic, M. Klasan (30); General
Hospital Zadar: Z. Bakotic, A. Anic (8); KBC Split: Z. Jurisic (8).
Poland (5 centres, 184 patients): Medical University of Lodz
(MUL) WAM Hospital: A. Lubinski, E. Kowalczyk, T. Kucejko, A.
Czechowska, K. Wybor (86); MUL CKD Hospital:
I. Cygankiewicz, P. Ptaszyński (41); MUL Bieganski Hospital,
Chair and Department of Cardiology: J. Kasprzak, H. Qavoq
(35); Poznan Medical University HSUH Hospital: P. Guzik,
T. Krauze (19); Institute of CardiologyWarsaw:M. Sterlinski (3).
Slovakia (2 centres, 159 patients): Slovak Medical University
NUSCH Bratislava: R. Hatala, M. Svetlosak (109); SUSSCH
Banska Bystrica: G. Kaliska, J. Martinek (50).
Denmark (2 centres, 143 patients): Rigshospitalet Copenha-
gen: J. Hastrup Svendsen, K. Thamsborg (60); Gentofte
Hospital, Copenhagen: J. Hansen, I.M. Schloett-Hyldelund,
J. Laage-Petersen (83).
Belgium (1 centre, 131 patients): Department of Cardiovascu-
lar Sciences, University of Leuven and University Hospitals
Leuven (KUL): R. Willems, B. Vandenberk, S. van Soest.
Greece (1 centre, 108 patients): Attikon University Hospital
Athens: P. Flevari, D. Katsaras, A. Katsimardos, D. Leftheriotis,
K. Papangelopoulou, C. Varlamos.
Bulgaria (4 centres, 105 patients): Acibadem City Clinic
Tokuda Hospital: V. Traykov (34); St. Anna Hospital:
V. Velchev (30); St. Ekaterina University Hospital: S. Iovev
(22); National Heart Hospital: T. Shalganov (19); all in Soﬁa.
Switzerland (1 centre, 74 patients): University Hospital Basel:
C. Sticherling, D. Conen, S. Giesebart.
Czech Republic (2 centres, 73 patients): University Hospital
Brno: T. Novotny, M. Kozak (39); University Hospital
Olomouc: M. Taborsky, J. Galuszka (34).
Netherlands (1 centre, 68 patients): University Medical Cen-
ter Utrecht, Department of Cardiology: A. E. Tuinenburg,
S. Wijers; Department of Medical Physiology: M.A. Vos,
S. Wijers, A. Dunnink, D. Sprenkeler.
Spain (1 centre, 61 patients): Hospital Clinic Barcelona,
Department of Cardiology, IDIBAPS: J. Brugada, E. Arbelo,
E. Trucco, S. Vidorreta.
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Finland (1 centre, 36 patients): University of Oulu Medical
Center: H. Huikuri, T. Kenttä, A. Pelli, P. Huikuri, P. Koski.
Sweden (2 centres, 16 patients): Karolinska Institute
Stockholm: F. Braunschweig, H. Karlsson, D. Ersgaard (14);
Lund University Hospital: P. Platonov (2).
Endpoint Adjudication Committee: G. Grönefeld,
T. Klingenheben.
List of EU-CERT-ICD project functionality
WP1 Prospective Study: Department of Cardiology, University
Medical Center Göttingen/Germany: M. Zabel, J. Seegers, L.
Bergau, G. Hasenfuß, P. Munoz-Exposito, T. Tichelbäcker, A.
Kirova, S. Schlögl, R. Sritharan, K. Jörß, J. Macken, M. Misdaq,
K. Rudolph.
WP02 Retrospective Registry: Department of Cardiology and
Clinical Trial Unit, University Hospital Basel/Switzerland: C.
Sticherling, M. Scharfe.
WP3 Health Economics: Charité Institute for Social
Medicine, Epidemiology and Health Economics,
Berlin/Germany: S. Willich, T. Reinhold, M. Cree.
WP4 Gender: Department of Cardiology, University Hospital -
Basel/Switzerland: D. Conen, C. Sticherling.
WP5 ECG core lab beat-to-beat variability of repolarization:
University Medical Center Utrecht, Department of Medical
Physiology: M.A. Vos, S. Wijers, A. Dunnink, D. Sprenkeler.
WP6 ECG core lab T-wave morphology: St. Paul’s
Electrophysiology/Imperial College London: M. Malik,
K. Hnatkova.
WP7 ECG core lab fractionation and early repolarization: De-
partment of Cardiology, University of Oulu Medical Center
Oulu/Finland: H. Huikuri, T. Kenttä, A. Pelli.
WP8 Holter Monitoring Core Lab: Department of Cardiology,
Klinikum rechts der Isar, Technische Universität München
Munich/Germany: G. Schmidt, A. Müller, J. Gerhardt, M.
Dommasch, D. Sinnecker,
WP8 Periodic Repolarization Dynamics: Department of Cardi-
ology, Klinikum Großhadern, Ludwig-Maximilians University
Munich/Germany: A. Bauer, K. Rizas, W. Hamm.
WP9 Biobanking: Department of Cardiology Klinikum
Großhadern, Ludwig-Maximilians University Munich/
Germany: S. Kääb, M. Sinner.
WP10 Statistics: Department of Medical Statistics, University
Medical Center Göttingen/Germany: T. Friede, C. Röver,
M. Harden, B. Kessel.
WP11 Dissemination: Hospital Clinic Barcelona/Spain, Depart-
ment of Cardiology, IDIBAPS: J. Brugada, E. Arbelo, E. Trucco.
WP12 Study Management: Institute for Clinical
Studies/Clinical Trial Unit (IFS/KSM), Study Center and Staff
Unit Clinical Studies at University Medical Center
Göttingen/Germany: A. Berg, E. Müller, S. Apel, F. Walker,
N. Kirchhof, S. Pfeiffer, A. Görlitz, A. Molitor, J. Heinrich.
WP13 Project Management: Gabo:mi Munich/Germany
(2013–2016): S. Annetzberger, B. Fuchs; EU International
Ofﬁce University Medical Center Göttingen/Germany: A.
Landwehr, A. Merk, A. Wilke, C. Hennecke, R. Mansch.
ECG, electrocardiogram
EU, European Union
WP, work package
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